| Inhibitory effect of tumor cell–derived lactic acid on human T cells K Fischer, P Hoffmann, S Voelkl, N Meidenbauer, J Ammer, M Edinger, ... Blood 109 (9), 3812-3819, 2007 | 1859 | 2007 |
| LDHA-associated lactic acid production blunts tumor immunosurveillance by T and NK cells A Brand, K Singer, GE Koehl, M Kolitzus, G Schoenhammer, A Thiel, ... Cell metabolism 24 (5), 657-671, 2016 | 1371 | 2016 |
| Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy C Blank, TF Gajewski, A Mackensen Cancer Immunology, Immunotherapy 54, 307-314, 2005 | 820 | 2005 |
| Tumor-derived lactic acid modulates dendritic cell activation and antigen expression E Gottfried, LA Kunz-Schughart, S Ebner, W Mueller-Klieser, S Hoves, ... Blood 107 (5), 2013-2021, 2006 | 726 | 2006 |
| Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion C Blank, A Mackensen Cancer immunology, immunotherapy 56, 739-745, 2007 | 655 | 2007 |
| Phase I study in melanoma patients of a vaccine with peptide‐pulsed dendritic cells generated in vitro from CD34+ hematopoietic progenitor cells A Mackensen, B Herbst, JL Chen, G Köhler, C Noppen, W Herr, ... International journal of cancer 86 (3), 385-392, 2000 | 501 | 2000 |
| Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance A Zippelius, P Batard, V Rubio-Godoy, G Bioley, D Liénard, F Lejeune, ... Cancer research 64 (8), 2865-2873, 2004 | 451 | 2004 |
| Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2 … C Röllig, H Serve, A Hüttmann, R Noppeney, C Müller-Tidow, U Krug, ... The lancet oncology 16 (16), 1691-1699, 2015 | 449 | 2015 |
| Blockade of PD‐L1 (B7‐H1) augments human tumor‐specific T cell responses in vitro C Blank, J Kuball, S Voelkl, H Wiendl, B Becker, B Walter, O Majdic, ... International journal of cancer 119 (2), 317-327, 2006 | 445 | 2006 |
| Bispecific T-cell engager (BiTE) antibody construct blinatumomab for the treatment of patients with relapsed/refractory non-Hodgkin lymphoma: final results from a phase I study ME Goebeler, S Knop, A Viardot, P Kufer, MS Topp, H Einsele, ... Journal of Clinical Oncology 34 (10), 1104-1111, 2016 | 442 | 2016 |
| Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma A Mackensen, N Meidenbauer, S Vogl, M Laumer, J Berger, R Andreesen Journal of Clinical Oncology 24 (31), 5060-5069, 2006 | 432 | 2006 |
| Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig–coated artificial antigen-presenting cells M Oelke, MV Maus, D Didiano, CH June, A Mackensen, JP Schneck Nature medicine 9 (5), 619-625, 2003 | 407 | 2003 |
| Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus A Mackensen, F Müller, D Mougiakakos, S Böltz, A Wilhelm, M Aigner, ... Nature medicine 28 (10), 2124-2132, 2022 | 388 | 2022 |
| Isolation and characterization of human antigen-specific TCRαβ+ CD4-CD8-double-negative regulatory T cells K Fischer, S Voelkl, J Heymann, GK Przybylski, K Mondal, M Laumer, ... Blood 105 (7), 2828-2835, 2005 | 363 | 2005 |
| Malignant melanoma S3‐guideline “diagnosis, therapy and follow‐up of melanoma” A Pflugfelder, C Kochs, A Blum, M Capellaro, C Czeschik, T Dettenborn, ... JDDG: Journal der Deutschen Dermatologischen Gesellschaft 11 (s6), 1-116, 2013 | 308 | 2013 |
| Presence of IgE antibodies to bovine serum albumin in a patient developing anaphylaxis after vaccination with human peptide-pulsed dendritic cells A Mackensen, R Dräger, M Schlesier, R Mertelsmann, A Lindemann Cancer Immunology, Immunotherapy 49, 152-156, 2000 | 302 | 2000 |
| CLL-cells induce IDOhi CD14+HLA-DRlo myeloid-derived suppressor cells that inhibit T-cell responses and promote TRegs R Jitschin, M Braun, M Büttner, K Dettmer-Wilde, J Bricks, J Berger, ... Blood, The Journal of the American Society of Hematology 124 (5), 750-760, 2014 | 276 | 2014 |
| Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells NR Mathew, F Baumgartner, L Braun, D O'Sullivan, S Thomas, ... Nature medicine 24 (3), 282-291, 2018 | 263 | 2018 |
| CD19-targeted CAR T cells in refractory systemic lupus erythematosus D Mougiakakos, G Krönke, S Völkl, S Kretschmann, M Aigner, ... New England Journal of Medicine 385 (6), 567-569, 2021 | 258 | 2021 |
| CAR-HEMATOTOX: a model for CAR T-cell–related hematologic toxicity in relapsed/refractory large B-cell lymphoma K Rejeski, A Perez, P Sesques, E Hoster, C Berger, L Jentzsch, ... Blood, The Journal of the American Society of Hematology 138 (24), 2499-2513, 2021 | 242 | 2021 |
